137 related articles for article (PubMed ID: 38884175)
21. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Brodsky RA; Young NS; Antonioli E; Risitano AM; Schrezenmeier H; Schubert J; Gaya A; Coyle L; de Castro C; Fu CL; Maciejewski JP; Bessler M; Kroon HA; Rother RP; Hillmen P
Blood; 2008 Feb; 111(4):1840-7. PubMed ID: 18055865
[TBL] [Abstract][Full Text] [Related]
22. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.
Hill A; Rother RP; Arnold L; Kelly R; Cullen MJ; Richards SJ; Hillmen P
Haematologica; 2010 Apr; 95(4):567-73. PubMed ID: 20145265
[TBL] [Abstract][Full Text] [Related]
23. The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria.
Kim JS; Lee JW; Kim BK; Lee JH; Chung J
Korean J Hematol; 2010 Dec; 45(4):269-74. PubMed ID: 21253430
[TBL] [Abstract][Full Text] [Related]
24. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
[TBL] [Abstract][Full Text] [Related]
25. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
Tomazos I; Sierra JR; Johnston KM; Cheung A; Brodsky RA; Weitz IC
Hematology; 2020 Dec; 25(1):327-334. PubMed ID: 32856539
[No Abstract] [Full Text] [Related]
26. Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan.
Mulherin BP; Yeh M; Al-Adhami M; Dingli D
Drugs R D; 2024 May; ():. PubMed ID: 38727860
[TBL] [Abstract][Full Text] [Related]
27. [Antibody therapy for paroxysmal nocturnal hemoglobinuria].
Nishimura JI
Rinsho Ketsueki; 2020; 61(8):929-936. PubMed ID: 32908057
[TBL] [Abstract][Full Text] [Related]
28. Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study.
Patriquin CJ; Bogdanovic A; Griffin M; Kelly RJ; Maciejewski JP; Mulherin B; Peffault de Latour R; Röth A; Selvaratnam V; Szer J; Al-Adhami M; Horneff R; Tan L; Yeh M; Panse J
Adv Ther; 2024 May; 41(5):2050-2069. PubMed ID: 38573482
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.
Wong RSM
Ther Adv Hematol; 2022; 13():20406207221114673. PubMed ID: 35923770
[TBL] [Abstract][Full Text] [Related]
30. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Lee JW; Kulasekararaj AG
Expert Opin Biol Ther; 2020 Mar; 20(3):227-237. PubMed ID: 32011183
[No Abstract] [Full Text] [Related]
31. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria.
Hill A; Hillmen P; Richards SJ; Elebute D; Marsh JC; Chan J; Mojcik CF; Rother RP
Blood; 2005 Oct; 106(7):2559-65. PubMed ID: 15985537
[TBL] [Abstract][Full Text] [Related]
32. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies.
Röth A; Rottinghaus ST; Hill A; Bachman ES; Kim JS; Schrezenmeier H; Terriou L; Urbano-Ispizua Á; Wells RA; Jang JH; Kulasekararaj AG; Szer J; Aguzzi R; Damokosh AI; Shafner L; Lee JW
Blood Adv; 2018 Sep; 2(17):2176-2185. PubMed ID: 30171081
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.
Kanakura Y; Ohyashiki K; Shichishima T; Okamoto S; Ando K; Ninomiya H; Kawaguchi T; Nakao S; Nakakuma H; Nishimura J; Kinoshita T; Bedrosian CL; Valentine ME; Khursigara G; Ozawa K; Omine M
Int J Hematol; 2011 Jan; 93(1):36-46. PubMed ID: 21222185
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria.
Wong RSM; Pullon HWH; Amine I; Bogdanovic A; Deschatelets P; Francois CG; Ignatova K; Issaragrisil S; Niparuck P; Numbenjapon T; Roman E; Sathar J; Xu R; Al-Adhami M; Tan L; Tse E; Grossi FV
Ann Hematol; 2022 Sep; 101(9):1971-1986. PubMed ID: 35869170
[TBL] [Abstract][Full Text] [Related]
35. Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria.
Heo YA
Drugs; 2022 Dec; 82(18):1727-1735. PubMed ID: 36459381
[TBL] [Abstract][Full Text] [Related]
36. Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea.
Kim JS; Jang JH; Jo DY; Ahn SY; Yoon SS; Lee JH; Kim SH; Choi CW; Shin HJ; Kim MK; Lee JH; Mun YC; Kong JH; Hyun B; Nam H; Kim E; Kwak MJ; Won YK; Lee JW
J Korean Med Sci; 2023 Oct; 38(41):e328. PubMed ID: 37873628
[TBL] [Abstract][Full Text] [Related]
37. Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls.
Risitano AM; Peffault de Latour R; Marano L; Frieri C
Semin Immunol; 2022 Jan; 59():101618. PubMed ID: 35764467
[TBL] [Abstract][Full Text] [Related]
38. Crovalimab: First Approval.
Dhillon S
Drugs; 2024 Jun; 84(6):707-716. PubMed ID: 38740735
[TBL] [Abstract][Full Text] [Related]
39. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy.
Versino F; Fattizzo B
Int J Lab Hematol; 2024 May; 46 Suppl 1():43-54. PubMed ID: 38622956
[TBL] [Abstract][Full Text] [Related]
40. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
